title: Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display.
abstract: Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by autoantibodies reactive with the pyruvate dehydrogenase complex. A conformational epitope has been mapped to aa 91-227 within the inner lipoyl domain of the E2 subunit (pyruvate dehydrogenase complex E2 (PDC-E2)). We have used phage display to further localize this epitope. A random heptapeptide library was screened using IgG from two patients with PBC, with negative selection using pooled normal IgG. Phage that contained peptide inserts (phagotopes) selected using PBC sera differed from those selected using IgG from patients with RA or polychondritis. Two motifs occurred only among the PBC-selected phagotopes; these were MH (13 sequences, 16 phagotopes) and FV (FVEHTRW, FVEIYSP, FVLPWRI). The phagotopes selected were tested for reactivity with anti-PDC-E2 affinity purified from four patients with PBC. Phagotopes that contained 1 of 15 different peptide sequences were reactive with one or more of these four anti-PDC-E2 preparations, whereas phagotopes that contained 1of the remaining 28 sequences were negative. The peptides (FVLPWRI, MHLNTPP, MHLTQSP) encoded by three phagotopes that were strongly reactive with all four preparations of anti-PDC-E2 were synthesized. Each of the selected peptides, but not an irrelevant peptide, inhibited the reactivity by ELISA of PBC serum with recombinant PDC-E2 and reduced the inhibition of the enzyme activity of PDC by a PBC serum. The peptide sequences, along with the known NMR structure of the inner lipoyl domain of PDC-E2, allow the prediction of nonsequential residues 131HM132 and 178FEV180 that contribute to a conformational epitope.
authors.affiliation: Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia. Merrill.Rowley@med.monash.edu.au
authors.forename: M J
authors.initials: MJ
authors.lastname: Rowley
authors.forename: M
authors.initials: M
authors.lastname: Scealy
authors.forename: J C
authors.initials: JC
authors.lastname: Whisstock
authors.forename: J A
authors.initials: JA
authors.lastname: Jois
authors.forename: L C
authors.initials: LC
authors.lastname: Wijeyewickrema
authors.forename: I R
authors.initials: IR
authors.lastname: Mackay
mesh_terms: D000595:Amino Acid Sequence; D000937:Antigen-Antibody Reactions; D017104:Bacteriophage M13 / Q000276:immunology; D051047:Dihydrolipoyllysine-Residue Acetyltransferase; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping / Q000379:methods; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000378:metabolism; D016056:Immunodominant Epitopes / Q000276:immunology / Q000302:isolation & purification* / Q000378:metabolism; D008105:Liver Cirrhosis, Biliary / Q000201:enzymology* / Q000276:immunology*; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000138:chemical synthesis / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology; D019151:Peptide Library; D011487:Protein Conformation; D011768:Pyruvate Dehydrogenase Complex / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000276:immunology*
chemical_list: D004791:Enzyme Inhibitors; D007106:Immune Sera; D016056:Immunodominant Epitopes; D009842:Oligopeptides; D019151:Peptide Library; D011768:Pyruvate Dehydrogenase Complex; D051047:Dihydrolipoyllysine-Residue Acetyltransferase